The Case of Tumour Necrosis Factor-α Inhibitors in the Treatment of Rheumatoid Arthritis: A Budget Impact Analysis

By Sørensen Jan  

PharmacoEconomics, Vol. 23, Iss. 3, 2005-01 ,pp. : 289-298

Adis International

Access to resources Recommend Favorite

Cost Effectiveness of Tumour Necrosis Factor-α Inhibitors as First-Line Agents in Rheumatoid Arthritis

By Spalding James R.  

PharmacoEconomics, Vol. 24, Iss. 12, 2006-01 ,pp. : 1221-1232

Adis International

Access to resources Recommend Favorite

Cost Utility of Tumour Necrosis Factor-α Inhibitors for Rheumatoid Arthritis: An Application of Bayesian Methods for Evidence Synthesis in a Markov Model

By Nguyen Christine M.   Bounthavong Mark   Mendes Margaret A.S.   Christopher Melissa L.D.   Tran Josephine N.   Kazerooni Rashid   Morreale Anthony P.  

PharmacoEconomics, Vol. 30, Iss. 7, 2012-07 ,pp. : 575-593

Adis International

Access to resources Recommend Favorite

Anti-Tumour Necrosis Factor-α Therapy for Rheumatoid and Other Inflammatory Arthropathies: Update on Safety in Older Patients

By Ornetti Paul   Chevillotte Hélène   Zerrak Amal   Jean Francis Maillefert  

Drugs & Aging, Vol. 23, Iss. 11, 2006-01 ,pp. : 855-860

Adis International

Access to resources Recommend Favorite

Safety of Tumour Necrosis Factor- Antagonists

By Khanna D.   McMahon M.   Furst D.E.  

Drug Safety, Vol. 27, Iss. 5, 2004-01 ,pp. : 307-324

Adis International

Access to resources Recommend Favorite